Comparative Pharmacology
Head-to-head clinical analysis: DITATE DS versus PENECORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DITATE DS versus PENECORT.
DITATE-DS vs PENECORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DITATE-DS is a combination of dexamethasone, a corticosteroid with anti-inflammatory and immunosuppressant properties, and trimethoprim, a folate antagonist. Dexamethasone acts by binding to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response. Trimethoprim inhibits dihydrofolate reductase, blocking bacterial folate synthesis and exerting antibacterial effects.
PENECORT is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation, immune responses, and adrenal function.
1 tablet (0.5 mg dexamethasone/5 mg cyproheptadine) orally every 8 hours, maximum 3 tablets daily.
2.5-5 mg orally once daily; maximum 10 mg/day. Intramuscular: 20-40 mg every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life: 3-4 hours in adults; prolonged in hepatic impairment (up to 8 hours).
Renal (50-60% as unchanged drug and metabolites), biliary/fecal (40-50% as metabolites and unchanged drug).
Renal: 60-70% as metabolites, 5-10% unchanged; Biliary/fecal: 20-30% as metabolites.
Category C
Category C
Corticosteroid
Corticosteroid